XTL Biopharmaceuticals Ltd. (XTLB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol XTLB
- Company XTL Biopharmaceuticals Ltd.
- Price $0.8
- Changes Percentage -3.68
- Change -0.03
- Day Low $0.7
- Day High $0.8
- Year High $2.57
- Year Low $0.53
- Market Cap $1,089,069
- Price Avg 50 EMA (D) $0.85
- Price Avg 200 EMA (D) $1.14
- Exchange NASDAQ
- Volume 12,356
- Average Volume 729,166
- Open $0.77
- Previous Close $0.83
- EPS -0.9
- PE -0.89
- Earnings Announcement 2025-12-29 05:00:00
- Shares Outstanding $1,362,358
Company brief: XTL BIOPHARMACEUTICALS LTD. (XTLB )
- Healthcare
- Biotechnology
- Mr. Shlomo Spokone Shalev
- https://www.xtlbio.com
- IL
- N/A
- 09-01-2005
- US98386D3070
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.